查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951866

单株抗体疗法市场分析及预测（至2035年）：依类型、产品类型、技术、应用、最终使用者、功能、流程、实施类型及发展阶段划分

Monoclonal Antibody Therapy Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Functionality, Process, Deployment, Stage
出版日期: | 出版商: Global Insight Services | 英文 397 Pages | 商品交期: 3-5个工作天内

价格
简介目录

单株抗体疗法市场预计将从2024年的1,865亿美元成长到2034年的4,975亿美元，复合年增长率约为12.4%。单株抗体疗法市场涵盖实验室合成分子的开发和分销，这些分子旨在作为替代抗体，恢復或增强免疫系统功能。这些疗法针对特定抗原，能够精准治疗癌症、自体免疫疾病和感染疾病等疾病。生物技术的进步、慢性病盛行率的上升以及对个人化医疗投资的增加是推动市场成长的主要因素，凸显了治疗方法标靶性和有效性不断提高的趋势。

受生物技术进步和慢性病发病率上升的推动，单株抗体疗法市场正经历强劲成长。肿瘤治疗领域成长最为显着，这主要得益于对标靶癌症治疗需求的不断增长。在该领域中，专注于查核点抑制剂的细分市场尤其引人注目，展现出巨大的治疗潜力。自体免疫疾病领域的成长速度位居第二，其中针对类风湿性关节炎和多发性硬化症的标靶治疗方法前景广阔。感染疾病领域也呈现成长势头，特别是针对新冠病毒和爱滋病等病毒感染疾病的单株抗体。双特异性抗体的创新透过提高特异性和疗效，进一步加速了市场成长。此外，市场正朝着人源化和完全人体单株抗体降低免疫抗原性并改善患者预后。持续的研发投入和策略合作有望推动未来的发展，并为治疗性介入开闢新的途径。

市场区隔
类型 鼠源的、嵌合体的、人源化的、人类的、双特异性的
产品 治疗性单株抗体、诊断性单株抗体
科技 融合瘤技术、重组DNA技术、噬菌体展示技术、基因转殖小鼠
适应症 癌症、自体免疫疾病、感染疾病、心血管疾病、神经系统疾病
最终用户 医院、研究机构、生物製药公司、诊断检查室
功能 中和作用、细胞毒性、抗发炎作用
过程 上游工程，下游过程
实施表格 内部、外包
步 临床前、临床、商业化

单株抗体疗法凭藉着创新的定价策略和新产品的大量上市，正迅速占据显着的市场份额。这一增长得益于生物技术的进步和对个人化医疗日益增长的关注。主要企业正不断强化产品系列，以因应不同的治疗领域，从而促进竞争和创新。价格趋势持续变化，受到对经济高效治疗方法和具有竞争力的定价模式的需求的影响。单株抗体疗法市场的竞争异常激烈，各大製药公司都在争夺主导。监管政策，尤其是在北美和欧洲，正在塑造市场动态，并确保安全性和有效性标准的落实。竞争对手的比较分析显示，策略联盟和併购已成为企业加强市场渗透的趋势。法规环境的持续变化影响企业的市场准入和扩大策略。为了因应这些挑战，各公司正加大研发投入，以期在肿瘤学和自体免疫疾病领域抓住新的机会。

主要趋势和驱动因素：

受生物技术进步和慢性病发病率上升的推动，单株抗体疗法市场正经历强劲成长。一个关键趋势是单株抗体在肿瘤领域的应用日益广泛。这种透过针对特定癌细胞来提高疗效的精准医疗方法备受关注，并显着扩大了市场规模。另一个趋势是生物相似药的开发，它们是品牌单株抗体的更经济实惠的替代品。这为新兴市场带来了新的机会，先前成本限制了这些疗法的普及。此外，监管机构正在简化生物相似药的核准流程，进一步加速了市场成长。抗体工程技术的创新也推动了市场发展，使得开发更有效、更安全的治疗方法成为可能。此外，製药公司和生技公司之间的合作正在促进研发活动，并推动新型单株抗体的问世。此类合作对于满足各个治疗领域尚未满足的需求至关重要，并有助于扩大市场格局。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 小鼠来源
    • 嵌合体体
    • 人性化
    • 人类
    • 双特异性抗体
  • 市场规模及预测：依产品划分
    • 治疗性单株抗体
    • 诊断用单株抗体
  • 市场规模及预测：依技术划分
    • 融合瘤技术
    • 重组DNA技术
    • 噬菌体展示
    • 基因改造小鼠
  • 市场规模及预测：依应用领域划分
    • 癌症
    • 自体免疫疾病
    • 感染疾病
    • 心血管疾病
    • 神经系统疾病
  • 市场规模及预测：依最终用户划分
    • 医院
    • 研究所
    • 生物製药公司
    • 诊断检查室
  • 市场规模及预测：依功能划分
    • 中和抗体
    • 细胞毒性
    • 消炎（药）
  • 市场规模及预测：依製程划分
    • 上游工程
    • 下游工艺
  • 市场规模及预测：依发展状况
    • 内部开发
    • 外包
  • 市场规模及预测：依发展阶段划分
    • 临床前阶段
    • 临床
    • 商业的

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Genmab
  • Morpho Sys
  • Macro Genics
  • Immuno Gen
  • Xencor
  • Zymeworks
  • Pieris Pharmaceuticals
  • Ab Cellera Biologics
  • Mab Vax Therapeutics
  • Onco Immune
  • Immunomedics
  • Alligator Bioscience
  • Bio Invent International
  • Crescendo Biologics
  • F-star Therapeutics
  • Adimab
  • Harpoon Therapeutics
  • I-Mab Biopharma
  • Cantargia

第九章：关于我们

简介目录
Product Code: GIS22022

Monoclonal Antibody Therapy Market is anticipated to expand from $186.5 billion in 2024 to $497.5 billion by 2034, growing at a CAGR of approximately 12.4%. The Monoclonal Antibody Therapy Market encompasses the development and distribution of lab-engineered molecules designed to serve as substitute antibodies, restoring or enhancing immune system function. These therapies target specific antigens, offering precision in treating diseases such as cancer, autoimmune disorders, and infectious diseases. The market is driven by advancements in biotechnology, increasing prevalence of chronic diseases, and growing investment in personalized medicine, underscoring a trend towards more targeted and effective treatment modalities.

The Monoclonal Antibody Therapy Market is experiencing robust growth, fueled by advancements in biotechnology and increasing prevalence of chronic diseases. The oncology segment is the top-performing area, driven by the rising demand for targeted cancer treatments. Within this segment, the sub-segment focusing on checkpoint inhibitors is particularly noteworthy, offering significant therapeutic potential. The autoimmune disorders segment emerges as the second highest-performing area, with therapies targeting rheumatoid arthritis and multiple sclerosis showing strong promise. The infectious diseases segment is also gaining momentum, especially with monoclonal antibodies targeting viral infections such as COVID-19 and HIV. Innovations in bispecific antibodies are further propelling market growth, offering enhanced specificity and efficacy. The market is also witnessing a shift towards humanized and fully human monoclonal antibodies, reducing immunogenicity and improving patient outcomes. Ongoing research and development, coupled with strategic partnerships, are anticipated to drive future advancements and open new avenues for therapeutic interventions.

Market Segmentation
TypeMurine, Chimeric, Humanized, Human, Bispecific
ProductTherapeutic Monoclonal Antibodies, Diagnostic Monoclonal Antibodies
TechnologyHybridoma Technology, Recombinant DNA Technology, Phage Display, Transgenic Mice
ApplicationCancer, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases, Neurological Diseases
End UserHospitals, Research Institutes, Biopharmaceutical Companies, Diagnostic Laboratories
FunctionalityNeutralizing, Cytotoxic, Anti-inflammatory
ProcessUpstream Processing, Downstream Processing
DeploymentIn-house, Outsourced
StagePreclinical, Clinical, Commercial

Monoclonal antibody therapy is gaining traction, with significant market share attributed to innovative pricing strategies and a surge in new product launches. This growth is fueled by advancements in biotechnology and a heightened focus on personalized medicine. Key players are enhancing their portfolios to cater to diverse therapeutic areas, driving competition and innovation. The pricing landscape remains dynamic, influenced by the need for cost-effective treatments and competitive pricing models. Competition in the monoclonal antibody therapy market is fierce, with major pharmaceutical companies vying for dominance. Regulatory influences, particularly in North America and Europe, shape market dynamics, ensuring safety and efficacy standards are met. Benchmarking against competitors reveals a trend toward strategic partnerships and mergers, enhancing market penetration. The regulatory environment continues to evolve, impacting market entry and expansion strategies. Companies are navigating these challenges by investing in research and development, seeking to capitalize on emerging opportunities in oncology and autoimmune diseases.

Geographical Overview:

The Monoclonal Antibody Therapy Market is witnessing robust growth across various regions, each presenting unique opportunities. North America remains at the forefront, driven by advanced healthcare infrastructure and substantial investment in biopharmaceutical research. The region's strong focus on innovative therapies and a supportive regulatory environment further bolster its market position. Europe follows closely, with significant investments in biotechnology and a well-established healthcare system. The region's emphasis on personalized medicine and strong collaboration between academia and industry enhance its market potential. In Asia Pacific, rapid growth is fueled by increasing healthcare expenditure and rising prevalence of chronic diseases. Emerging economies like China and India are investing heavily in biopharmaceuticals, creating new growth pockets. Latin America and the Middle East & Africa are emerging markets with increasing potential. In Latin America, growing healthcare investments and improving access to advanced therapies are driving market expansion. Similarly, the Middle East & Africa are recognizing the importance of monoclonal antibody therapies in addressing unmet medical needs and fostering healthcare innovation.

The global monoclonal antibody therapy market is increasingly influenced by tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea, traditionally reliant on Western biopharmaceutical imports, are investing in domestic production capabilities to mitigate tariff impacts and ensure supply chain resilience. China is accelerating its innovation in biologics, spurred by geopolitical tensions and export restrictions, while Taiwan leverages its advanced manufacturing expertise to remain a pivotal player. Globally, the market is expanding, driven by rising demand for targeted therapies. By 2035, the market is expected to witness robust growth, contingent on geopolitical stability and diversified supply chains. Middle East conflicts, while indirectly affecting the market, could influence energy prices, thereby impacting production costs and logistics within the global supply chain.

Key Trends and Drivers:

The monoclonal antibody therapy market is experiencing robust growth, driven by advancements in biotechnology and rising prevalence of chronic diseases. A key trend is the increasing adoption of monoclonal antibodies in oncology, where they are used to target specific cancer cells, enhancing treatment efficacy. This precision medicine approach is gaining traction, leading to significant market expansion. Another trend is the development of biosimilars, which are more affordable alternatives to branded monoclonal antibodies. This is opening up new opportunities in emerging markets, where cost constraints have previously limited access to these therapies. Additionally, regulatory bodies are streamlining approval processes for biosimilars, further accelerating market growth. The market is also being driven by technological innovations in antibody engineering, enabling the creation of more potent and safer therapies. Moreover, partnerships between pharmaceutical companies and biotech firms are fostering research and development initiatives, leading to the introduction of novel monoclonal antibodies. These collaborations are crucial in addressing the unmet needs in various therapeutic areas, thus expanding the market landscape.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Functionality
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Murine
    • 4.1.2 Chimeric
    • 4.1.3 Humanized
    • 4.1.4 Human
    • 4.1.5 Bispecific
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Monoclonal Antibodies
    • 4.2.2 Diagnostic Monoclonal Antibodies
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Hybridoma Technology
    • 4.3.2 Recombinant DNA Technology
    • 4.3.3 Phage Display
    • 4.3.4 Transgenic Mice
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Cancer
    • 4.4.2 Autoimmune Diseases
    • 4.4.3 Infectious Diseases
    • 4.4.4 Cardiovascular Diseases
    • 4.4.5 Neurological Diseases
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Research Institutes
    • 4.5.3 Biopharmaceutical Companies
    • 4.5.4 Diagnostic Laboratories
  • 4.6 Market Size & Forecast by Functionality (2020-2035)
    • 4.6.1 Neutralizing
    • 4.6.2 Cytotoxic
    • 4.6.3 Anti-inflammatory
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Upstream Processing
    • 4.7.2 Downstream Processing
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 In-house
    • 4.8.2 Outsourced
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Preclinical
    • 4.9.2 Clinical
    • 4.9.3 Commercial

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Functionality
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Functionality
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Functionality
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Functionality
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Functionality
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Functionality
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Functionality
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Functionality
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Functionality
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Functionality
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Functionality
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Functionality
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Functionality
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Functionality
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Functionality
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Functionality
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Functionality
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Functionality
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Functionality
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Functionality
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Functionality
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Functionality
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Functionality
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Functionality
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Genmab
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Morpho Sys
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Macro Genics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Immuno Gen
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Xencor
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Zymeworks
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Pieris Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Ab Cellera Biologics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Mab Vax Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Onco Immune
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Immunomedics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Alligator Bioscience
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Bio Invent International
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Crescendo Biologics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 F-star Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Adimab
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Harpoon Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 I- Mab Biopharma
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Cantargia
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us